Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.

Authors: Nicolas Sayegh, Yeonjung Jo, Zeynep Irem Ozay, Chadi Hage Chehade, Georges Gebrael, Micah Ostrowski, Patrick Campbell, Nishita Tripathi, Siqi HU, Beverly Chigarira, Ethan Anderson, Richard Ji, Gliceida Galarza Fortuna, Vinay Mathew Thomas, Haoran Li, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.82

Source: Full article

Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.

Abstract